Abiopharma

Agi to Announce First Quarter 2026 Financial Results on May 5, 2026

Perfect Announces Appointment of Financial Advisor and Legal Counsel to the Special Committee

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer

NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Phillips 66 and Kinder Morgan Advance Western Gateway Pipeline Project Following Successful Open Season

OpenText Appoints James McGourlay as President, Chief Client Officer

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

Brady Corporation to Acquire Honeywell’s Productivity Solutions and Services Business, Expanding Portfolio with Data Capture and Workflow Solutions

Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

(99% Neutral) NEOGEN CORP (NEOG) Announces Regulatory Update

Director Nelson Shawn David 🟢 acquired 1.5K shares of Lovesac Co (LOVE) at $16.95 Transaction Date: Apr 16, 2026 | Filing ID: 025915

ALTERITY THERAPEUTICS LTD (ATHE) Files Form 6-K